Cargando…

3D culture of Her2+ breast cancer cells promotes AKT to MAPK switching and a loss of therapeutic response

BACKGROUND: The Her2 receptor is overexpressed in up to 25 % of breast cancers and is associated with a poor prognosis. Around half of Her2+ breast cancers also express the estrogen receptor and treatment for such tumours can involve both endocrine and Her2-targeted therapies. However, despite precl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gangadhara, Sharath, Smith, Chris, Barrett-Lee, Peter, Hiscox, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4888214/ https://www.ncbi.nlm.nih.gov/pubmed/27251376 http://dx.doi.org/10.1186/s12885-016-2377-z

Ejemplares similares

Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women
por: Gangadhara, Sharath, et al.
Publicado: (2009)

Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells
por: Borley, Annabel C, et al.
Publicado: (2008)

Detection of phosphorylated Akt and MAPK in cell culture assays
por: Molgaard, Simon, et al.
Publicado: (2016)

Loss of PR55α promotes proliferation and metastasis by activating MAPK/AKT signaling in hepatocellular carcinoma
por: Zhao, JiangSheng, et al.
Publicado: (2021)

PELP-1 regulates adverse responses to endocrine therapy in Estrogen Receptor (ER) positive breast cancer
por: Rees, Michael, et al.
Publicado: (2020)

Role of the Balance of Akt and MAPK Pathways in the Exercise-Regulated Phenotype Switching in Spontaneously Hypertensive Rats
por: Zhang, Lin, et al.
Publicado: (2019)

HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway
por: Smith, Alison E., et al.
Publicado: (2021)

Osthole Synergizes With HER2 Inhibitor, Trastuzumab in HER2-Overexpressed N87 Gastric Cancer by Inducing Apoptosis and Inhibition of AKT-MAPK Pathway
por: Yang, Yun, et al.
Publicado: (2018)

Diagnostics and Therapeutics in Targeting HER2 Breast Cancer: A Novel Approach
por: Vi, Chris, et al.
Publicado: (2021)

Expression of CD24 is associated with HER2 expression and supports HER2-Akt signaling in HER2-positive breast cancer cells
por: Hosonaga, Mari, et al.
Publicado: (2014)

Obesity enhances nongenomic estrogen receptor crosstalk with the PI3K/Akt and MAPK pathways to promote in vitro measures of breast cancer progression
por: Bowers, Laura W, et al.
Publicado: (2013)

Actein Inhibits Tumor Growth and Metastasis in HER2-Positive Breast Tumor Bearing Mice via Suppressing AKT/mTOR and Ras/Raf/MAPK Signaling Pathways
por: Wu, Xiao-Xiao, et al.
Publicado: (2020)

Melatonin Attenuates Her-2, p38 MAPK, p-AKT, and mTOR Levels in Ovarian Carcinoma of Ethanol-Preferring Rats
por: Ferreira, Grazielle M., et al.
Publicado: (2014)

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences
por: Kruger, Dinja T., et al.
Publicado: (2018)

Asporin Interacts With HER2 to Promote Thyroid Cancer Metastasis via the MAPK/EMT Signaling Pathway
por: Zhan, Shaohua, et al.
Publicado: (2022)

The role of MAPK signaling pathway in the Her-2-positive meningiomas
por: Wang, Zhaoyin, et al.
Publicado: (2016)

Inhibition of KDM5A attenuates cisplatin-induced hearing loss via regulation of the MAPK/AKT pathway
por: Liu, Chang, et al.
Publicado: (2022)

Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer
por: LeVee, Alexis, et al.
Publicado: (2023)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

MYH9 Promotes Growth and Metastasis via Activation of MAPK/AKT Signaling in Colorectal Cancer
por: Wang, Bin, et al.
Publicado: (2019)

Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway
por: Zhu, Hui-er, et al.
Publicado: (2019)

MAPK6-AKT signaling promotes tumor growth and resistance to mTOR kinase blockade
por: Cai, Qinbo, et al.
Publicado: (2021)

Pyrotinib as a therapeutic for HER2-positive breast cancer
por: Kioutchoukova, Ivelina, et al.
Publicado: (2023)

The effect of FSH and activin A on Akt and MAPK1/3 phosphorylation in cultured bovine ovarian cortical strips
por: Tepekoy, Filiz, et al.
Publicado: (2016)

Heat shock protein 20 suppresses breast carcinogenesis by inhibiting the MAPK and AKT signaling pathways
por: Yang, Yinxi, et al.
Publicado: (2022)

Hypermethylation of MAPK13 Promoter in Oesophageal Squamous Cell Carcinoma Is Associated with Loss of p38δ MAPK Expression
por: O′Callaghan, Carol, et al.
Publicado: (2015)

Resveratrol chemosensitizes HER-2-overexpressing breast cancer cells to docetaxel chemoresistance by inhibiting docetaxel-mediated activation of HER-2–Akt axis
por: Vinod, B S, et al.
Publicado: (2015)

Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer
por: Wang, Jinlu, et al.
Publicado: (2020)

PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening
por: Lee, Jangsoon, et al.
Publicado: (2021)

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer
por: Mezynski, M. Janusz, et al.
Publicado: (2021)

Downregulation of OSR1 Promotes Colon Adenocarcinoma Progression via FAK-Mediated Akt and MAPK Signaling
por: Zhang, Fang, et al.
Publicado: (2020)

ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
por: Pinhel, Isabel, et al.
Publicado: (2012)

Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
por: Wu, Yanyuan, et al.
Publicado: (2008)

The HSP-RTK-Akt axis mediates acquired resistance to Ganetespib in HER2-positive breast cancer
por: Eyermann, Christopher E., et al.
Publicado: (2021)

Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
por: Liu, Peng, et al.
Publicado: (2019)

IL-1β Promotes Vasculogenic Mimicry of Breast Cancer Cells Through p38/MAPK and PI3K/Akt Signaling Pathways
por: Nisar, Muhammad Azhar, et al.
Publicado: (2021)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020)

Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer
por: Ko, Eunkyung, et al.
Publicado: (2010)

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity
por: Lindberg, Karolina, et al.
Publicado: (2011)

HER2 inhibition increases non-muscle myosin IIA to promote tumorigenesis in HER2+ breast cancers
por: Alanazi, Samar M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2ghkialsrogvhkg7subeu6rvnk